Condensed Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended
	Dec. 31, 2011	Dec. 31, 2010
REVENUE:
GRANT INCOME AND OTHER	$ 5,024	$ 662,818
OPERATING EXPENSES:
Research and development (excluding R&D depreciation of $114,612 and $116,191 respectively, included below)	2,456,185	3,264,428
Depreciation and amortization	138,425	141,147
General and administrative	1,853,690	1,573,277
Total operating expenses	4,448,300	4,978,852
OPERATING LOSS	(4,443,276)	(4,316,034)
GAIN (LOSS) ON DERIVATIVE INSTRUMENTS	956,470	(1,946,395)
INTEREST INCOME	29,055	52,879
INTEREST EXPENSE	(123,462)	(41,402)
NET LOSS	(3,581,213)	(6,250,952)
ISSUANCE OF ADDITIONAL SHARES	(250,000)	0
MODIFICATION OF WARRANTS	(325,620)	0
NET LOSS AVAILABLE TO COMMON SHAREHOLDERS	$ (4,156,833)	$ (6,250,952)
NET (LOSS) INCOME PER COMMON SHARE-BASIC	$ (0.02)	$ (0.03)
NET LOSS PER COMMON SHARE-DILUTED	$ (0.02)	$ (0.03)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING-BASIC	228,568,435	205,112,418
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING-DILUTED	228,568,435	205,112,418